Lyon and Indianapolis, May 31, 2016 – Adocia (Euronext Paris: ADOC) and Eli Lilly and Company (NYSE: LLY) announced today positive topline results from a Phase 1 clinical trial evaluating BioChaperone Lispro, an ultra-rapid formulation
A recent study has found that insulin treatment is not responsible for the poorer health… Read More
Listen to today’s podcast here!
New research shows that women who are taking insulin for diabetes treatment are at a higher… Read More
Researchers recently completed a study to find out how the risk of fracture differed with the type of insulin therapy used by people with type 2 diabetes. While it is known that there is an increased risk of fracture associated with type 2 diabetes,… Read More